Study examines GLP-1 receptor agonist use and risk of neovascular age-related macular degeneration, providing important eye safety data for this widely used drug class.
Key findingStudy examines GLP-1 receptor agonist use and risk of neovascular age-related macular degeneration,
What the researchers found
Study examines GLP-1 receptor agonist use and risk of neovascular age-related macular degeneration, providing important eye safety data for this widely used drug class.
Why it matters
Relevant to the expanding applications of peptide-based therapies in medicine.
The numbers in context
Large US cohort study with 1, 2, and 3-year follow-up periods showing consistent risk reduction for neovascular AMD in GLP-1 users.
How the study worked
Study methodology detailed in the full publication.
Who was studied
US adults over 60 with ophthalmology follow-up from the TriNetX health records network
What this study cannot tell us
Limitations discussed in the full publication.
How to read the evidence
Evidence level based on study design.
When this study was published
Published in 2025.
The bigger picture
Contributes to the growing body of evidence for peptide therapeutics across medical specialties.
Questions still open
- What are the long-term implications?
- How do results compare to existing evidence?
- What research is needed next?
Common questions
What does this mean for patients?
How reliable is this?
Read the original research
Glucagon-Like Peptide-1 Receptor Agonist Use and Risk of Neovascular Age-Related Macular Degeneration in a National Cohort Study.
Ophthalmology. Retina
Citation
Allan, Kevin C; Cohn, Erin F; Bala, Suraj; Kim, Sonia B; Kaelber, David C; Singh, Rishi P; Talcott, Katherine E; Mammo, Danny A; Rachitskaya, Aleksandra V. (2025). Glucagon-Like Peptide-1 Receptor Agonist Use and Risk of Neovascular Age-Related Macular Degeneration in a National Cohort Study.. Ophthalmology. Retina. https://doi.org/10.1016/j.oret.2025.10.020